ReviewPurinergic signalling2026
Adenosine A2A receptor signaling in neuroinflammation, glial modulation, and mechanisms associated with chronic pain.
Review in Purinergic signalling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pain is increasingly recognized as a complex and multidimensional condition that extends beyond peripheral nociceptive input, encompassing maladaptive central mechanisms such as persistent neuroinflammation, glial dysfunction, aberrant synaptic plasticity, and disturbances in affective-motivational circuits. Adenosine, an endogenous purine nucleoside, plays a pivotal role in central nervous system homeostasis through activation of four G protein-coupled receptors (A1, A2A, A2B, and A3). Among these, the adenosine A2A receptor (A2AR) has emerged as an important modulator of neuroimmune signaling, astrocyte-neuron communication, synaptic excitability, and behavior. Although adenosinergic signaling has been extensively investigated in the context of pain and neurological disorders, the specific contribution of A2AR to pain-related mechanisms is often addressed indirectly, as many studies focus on upstream neurobiological processes rather than nociception itself. In this narrative review, we integrate recent experimental, translational and observational evidence from in silico, in vitro, ex vivo, in vivo, and human studies to examine how A2AR-dependent signaling may influence mechanisms associated with pain modulation. The literature is organized according to conceptual and mechanistic criteria into four thematic axes: (i) neuroinflammation and central sensitization, (ii) astrocytic regulation and synaptic modulation, (iii) neurological disorders with pain-related components, and (iv) affective and emotional processes associated with the pain experience. Across these domains, convergent evidence suggests that A2AR signaling is involved in interactions between glial activation, inflammatory signaling, synaptic plasticity, and affective regulation. Together, these findings provide a framework for understanding how A2AR-related mechanisms contribute to process associated with chronic pain development and persistence, even in experimental contexts not explicitly designed to assess nociception. This integrative perspective supports further investigation of A2AR as a potential therapeutic target in chronic pain and related neuroinflammatory conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.